EBR
Asset Logo

EBR Systems Inc.

πŸ‡¦πŸ‡Ί ASX

🩺 HEALTH CARE

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

+ 17.25%
Annual Growth

3 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

11
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

EBR Systems, Inc. engages in the development of implantable systems for wireless tissue stimulation. The company is headquartered in Sunnyvale, California. The company went IPO on 2021-11-24. The firm is engaged in developing and commercializing Wireless Stimulation Endocardially (WiSE), an implantable, cardiac pacing device able to provide stimulation to endocardial (inside the heart) heart tissue for the correction of heart rhythm conditions without requiring the use of leads. WiSE offers leadless solutions for LV Pacing, including cardiac resynchronization therapy (CRT) and conduction system pacing (CSP). The firm also offers CRT devices through the CRM subsegment under the brand names, including Visionist X4 CRT-P, Valitude X4 (CRT-P), Momentum CRT-D, Resonate X4 CRT-D, and Vigilant X4 CRT-D, among others. The firm operates various subsidiaries, which include EBR Systems (AUST) Pty. Ltd. and EBR Systems (UK) Limited, which establish clinical trials in Australia and the United Kingdom, respectively.

πŸ“ˆ Performance

Price History

+54.63%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$1.67

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in EBR

12

πŸ“Š Total Capital Earnings

$24K

πŸ”ƒ Average investment frequency

40 weeks

πŸ’΅ Average investment amount

$2,107

⏰ Last time a customer invested in EBR

1 day
EBR investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

8%

100k - 150k

17%

50k - 100k

33%

Less than 50k

42%
πŸ‘Ά Age of investors

18 - 25

26 - 34

25%

35 - 90

75%
πŸ™‹ Legal gender of investors

Female

33%

Male

67%

Pearlers who invest in EBR also invest in...

Vanguard Diversified High Growth Index ETF

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

3.31%

πŸ“Š Share price

$69.80 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

Find Out More

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

πŸ™Œ Performance (5Yr p.a)

19.59%

πŸ“Š Share price

$64.52 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The company develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. The company operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. The company operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.

πŸ™Œ Performance (5Yr p.a)

350.41%

πŸ“Š Share price

$26.86 AUD

🧬 BIOTECHNOLOGY

Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-02-11. The company owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Napperby Uranium, Yerelina and Mt Freeling, and Blueys-Inkheart. The Shoobridge Lithium Project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. The Anningie and Barrow Creek encompass eight exploration licenses over approximately 2,000 km2 in and around the Anningie and Barrow Creek tin-tantalum pegmatite fields in the Northern Territory. Napperby is an advanced uranium project within the central Northern Territory.

πŸ™Œ Performance (5Yr p.a)

30.00%

πŸ“Š Share price

$0.10 AUD

πŸ“ˆ HIGH PRICE GROWTH

⛏️ MINING

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

πŸ™Œ Performance (5Yr p.a)

25.21%

πŸ“Š Share price

$51.68 AUD

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

Want more shares? Try these...

EBTC.AX was created on 2022-05-09 by Global X. The fund's investment portfolio concentrates primarily on long btc, short usd currency. The investment objective of the Coin Interests issued by the Fund is to provide a return that tracks the performance of the price of Bitcoin in Australian dollars (before fees and expenses) by reference to the US dollar Crypto Coin Comparison Aggregated Index converted to Australian dollars.

πŸ“Š Share price

$15.96 AUD

Elanor Commercial Property Fund is a real estate investment trust. The company is headquartered in Sydney, New South Wales. The company went IPO on 2019-12-06. The Fund invests in commercial properties located in major metropolitan areas or established commercial precincts. The Fund's objective is to provide strong, risk-adjusted returns through a combination of regular distributions and capital growth. To achieve this objective, the Fund's strategy is to invest in commercial office properties with differentiated competitive market positions that are located in major metropolitan areas or established commercial precincts; execute leasing strategies and actively manage the properties to grow the income and capital value of the assets; acquire additional high investment quality commercial office properties in line with the Fund's investment criteria, and maintain a conservative capital structure with a target gearing range between 30% and 40%. The firm is managed by Elanor Funds Management Limited.

πŸ™Œ Performance (5Yr p.a)

-10.63%

πŸ“Š Share price

$0.61 AUD

πŸ’° HIGH DIVIDEND

🏠 REAL ESTATE

EBND.AX was created on 2020-02-11 by VanEck. The fund's investment portfolio concentrates primarily on broad credit fixed income. The ETF currently has 169.89m in AUM and 101 holdings. EBND.AX aims to provide investors with a globally diversified portfolio of bonds and currencies in emerging markets. The fund aims to provide total investment returns, measured over the medium to long term in excess of the Benchmark

πŸ“Š Share price

$10.23 AUD

EBOS Group Ltd. engages in the provision of healthcare and animal care products and services. The firm is a marketer and distributor of animal care brands. Its segments include Healthcare, Animal Care, and Corporate. The Healthcare segment includes sales of healthcare products in a range of sectors, own brands, retail healthcare, pharmacy, hospital and logistic services, and wholesale activities. The Animal Care segment includes sales of animal care products in a range of sectors, own manufactured and contract manufactured brands, retail, and wholesale activities. The company sources and supplies a range of surgical, medical, and pharmaceutical products. Its Community Pharmacy business includes Symbion, ProPharma, Pharmacy Wholesalers Russells, TerryWhite Chemmart, Good Price Pharmacy Warehouse, healthSAVE, Ventura Health, Minfos, DoseAid, Intellipharm, Endeavour Consumer Health, and Red Seal. Its contract logistics include Healthcare Logistics and Clinect.

πŸ™Œ Performance (5Yr p.a)

8.03%

πŸ“Š Share price

$33.00 AUD

πŸ“ˆ HIGH PRICE GROWTH

🩺 HEALTH CARE

Compare
Add to watchlist